Integra LifeSciences' stock plunges 25% after Q1 loss and reduced profit forecasts.

Integra LifeSciences saw its stock drop by nearly 25% to $12.78 after reporting a Q1 net loss of $25.3 million, up from $3.3 million last year. Despite a slight revenue increase to $382.7 million, the company adjusted its EPS guidance due to tariff impacts. Integra reaffirmed its 2025 revenue forecast but reduced profit expectations due to quality issues and slower sales in key areas. Shares have been volatile, with 21 moves over 5% in the past year.